Analyzing Tempus AI (NASDAQ:TEM) and Aspyra (OTCMKTS:APYI)
by Sarita Garza · The Markets DailyTempus AI (NASDAQ:TEM – Get Free Report) and Aspyra (OTCMKTS:APYI – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Tempus AI and Aspyra’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -18.45% | -73.21% | -13.78% |
| Aspyra | N/A | N/A | N/A |
Institutional and Insider Ownership
24.2% of Tempus AI shares are held by institutional investors. 26.3% of Tempus AI shares are held by company insiders. Comparatively, 23.9% of Aspyra shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Tempus AI and Aspyra, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 1 | 7 | 7 | 0 | 2.40 |
| Aspyra | 0 | 0 | 0 | 0 | 0.00 |
Tempus AI presently has a consensus target price of $83.09, suggesting a potential upside of 17.68%. Given Tempus AI’s stronger consensus rating and higher possible upside, research analysts plainly believe Tempus AI is more favorable than Aspyra.
Earnings & Valuation
This table compares Tempus AI and Aspyra”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $1.11 billion | 11.37 | -$705.81 million | ($1.19) | -59.34 |
| Aspyra | N/A | N/A | N/A | N/A | N/A |
Aspyra has lower revenue, but higher earnings than Tempus AI.
Volatility and Risk
Tempus AI has a beta of 4.99, suggesting that its share price is 399% more volatile than the S&P 500. Comparatively, Aspyra has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.
Summary
Tempus AI beats Aspyra on 7 of the 10 factors compared between the two stocks.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
About Aspyra
Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.